Corporate

Corporate

Bioeksen R&D Technologies is an Istanbul Technical University ARI Teknokent company established in 2014 with the support of KOSGEB R&D Innovation. Founders of Bioeksen are academicians who are members of the Microbial Ecology Group (MEG), a joint organization of Istanbul Technical and Bogazici Universities.


Bioeksen is an R&D and production company focused on innovative molecular technologies.


32 different R&D projects have been completed since our establishment, and as a result of these projects, 164 different molecular biotechnology products have been released in the areas of human health, animal health, and food safety. 


Bioeksen's innovation focuses on molecular technologies enabling healthcare providers to rapidly identify specific infections and to make timely clinical management decisions (e.g. hospitalization, isolation and antimicrobial treatment or lack thereof). Bioeksen's innovation focuses on molecular technologies detecting the disease agents in their source to timely control the transmission to human. Bioeksen has been carrying out extensive research on infectious agent specific molecular therapeutics to combine power of its molecular diagnostics technologies with the targeted treatment that has not any side effects to human.    


Bioeksen has a production capacity of 2 million tests/day. Approximately 140 million Bioeksen’s tests have been used in more than 55 different countries so far. Bioeksen has two different production facilities located in Turkey and Germany. Bioeksen operates ISO 13485 and 9001 quality management systems. Bioeksen’s molecular diagnostics solutions are in the top 5% that have both FDA and WHO approval among the 480 companies producing molecular tests in the world.


Bioeksen aims to be the global pioneer in the diagnosis and treatment of infectious diseases by integrating fast and reliable molecular diagnostic technology with molecular drugs specific to the disease agent.Bioeksen aims to be the global pioneer in the diagnosis and treatment of infectious diseases by integrating fast and reliable molecular diagnostic technology with molecular drugs specific to the disease agent.aims to be the global pioneer in the diagnosis and treatment of infectious diseases


Vision:


Our vision is to provide solutions from sample to result by making continuous research and development and increasing our production quality standards day by day to offer more practical, fast, and precise solutions to the laboratory employees who deliver the millions of tests we produce to society.